[
  {
    "ts": null,
    "headline": "RFK Jr.’s Team Wanted to Tout an Autism Therapy. He Went After Tylenol Instead.",
    "summary": "RFK Jr.’s Team Wanted to Tout an Autism Therapy. He Went After Tylenol Instead.",
    "url": "https://finnhub.io/api/news?id=a0ae1b881e9c87d69087da2f516afb4d72b45456f976df255923a4e29bdc6320",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758747600,
      "headline": "RFK Jr.’s Team Wanted to Tout an Autism Therapy. He Went After Tylenol Instead.",
      "id": 136932277,
      "image": "",
      "related": "KVUE",
      "source": "DowJones",
      "summary": "RFK Jr.’s Team Wanted to Tout an Autism Therapy. He Went After Tylenol Instead.",
      "url": "https://finnhub.io/api/news?id=a0ae1b881e9c87d69087da2f516afb4d72b45456f976df255923a4e29bdc6320"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Slips as Regulatory Fears Linger - Health Care Roundup",
    "summary": "Health Care Slips as Regulatory Fears Linger - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=7573b72942c786c47b6e42142c5b9508c721761b54dac5b681fb2b22fa3a1b45",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758734340,
      "headline": "Health Care Slips as Regulatory Fears Linger - Health Care Roundup",
      "id": 136932304,
      "image": "",
      "related": "KVUE",
      "source": "MarketWatch",
      "summary": "Health Care Slips as Regulatory Fears Linger - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=7573b72942c786c47b6e42142c5b9508c721761b54dac5b681fb2b22fa3a1b45"
    }
  },
  {
    "ts": null,
    "headline": "As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?",
    "summary": "Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.",
    "url": "https://finnhub.io/api/news?id=cca9dce5b6c09067b1ee76bcb9bc3e5bc30d00c5332230a585e94beab7fa1c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758733927,
      "headline": "As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?",
      "id": 136866014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.",
      "url": "https://finnhub.io/api/news?id=cca9dce5b6c09067b1ee76bcb9bc3e5bc30d00c5332230a585e94beab7fa1c69"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue: This Too Shall Pass",
    "summary": "Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.",
    "url": "https://finnhub.io/api/news?id=5c5dca700ec592542d80e904609f9d7ded7926baf522aad5e523d5dbb95c1500",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758724588,
      "headline": "Kenvue: This Too Shall Pass",
      "id": 136864111,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458559027/image_458559027.jpg?io=getty-c-w1536",
      "related": "KVUE",
      "source": "SeekingAlpha",
      "summary": "Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.",
      "url": "https://finnhub.io/api/news?id=5c5dca700ec592542d80e904609f9d7ded7926baf522aad5e523d5dbb95c1500"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Alibaba, Lithium Americas, GM",
    "summary": "↗️ Alibaba (HK: 9988, BABA): The Chinese tech giant's shares jumped 9% in Hong Kong after it unveiled plans to boost investment in AI to more than $53 billion. Its U.S.-listed shares also rallied Wednesday.",
    "url": "https://finnhub.io/api/news?id=a54286e6159ca12a841129ae52f1b3e42ff1468f70f3db61a2826eefd0e881e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758721640,
      "headline": "Stocks to Watch Wednesday: Alibaba, Lithium Americas, GM",
      "id": 136861717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "↗️ Alibaba (HK: 9988, BABA): The Chinese tech giant's shares jumped 9% in Hong Kong after it unveiled plans to boost investment in AI to more than $53 billion. Its U.S.-listed shares also rallied Wednesday.",
      "url": "https://finnhub.io/api/news?id=a54286e6159ca12a841129ae52f1b3e42ff1468f70f3db61a2826eefd0e881e4"
    }
  },
  {
    "ts": null,
    "headline": "Tylenol maker Kenvue faces mounting crisis after Trump blast",
    "summary": "Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it.  The US Food and Drug Administration has initiated the process for a label change to products containing acetaminophen that will say the ingredient is associated with a higher risk of autism in children when taken by pregnant women.  If the FDA succeeds in forcing Kenvue to add the autism risks to Tylenol’s label, consumers who sue to hold the company responsible for their child’s autism will likely be able to use the new warnings as evidence in court, plaintiffs’ lawyers say.",
    "url": "https://finnhub.io/api/news?id=6395d731eebf2d8c2c7f8af0bc222e19f04caf34b13087c6ec0dae38464b6efe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758721045,
      "headline": "Tylenol maker Kenvue faces mounting crisis after Trump blast",
      "id": 136862115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it.  The US Food and Drug Administration has initiated the process for a label change to products containing acetaminophen that will say the ingredient is associated with a higher risk of autism in children when taken by pregnant women.  If the FDA succeeds in forcing Kenvue to add the autism risks to Tylenol’s label, consumers who sue to hold the company responsible for their child’s autism will likely be able to use the new warnings as evidence in court, plaintiffs’ lawyers say.",
      "url": "https://finnhub.io/api/news?id=6395d731eebf2d8c2c7f8af0bc222e19f04caf34b13087c6ec0dae38464b6efe"
    }
  },
  {
    "ts": null,
    "headline": "Is There Now an Opportunity in Kenvue After Latest 20% Share Price Drop?",
    "summary": "If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take a hit lately, dipping 4.9% in the past week and slipping more than 20% over the last month. It has been a rough ride for the stock so far this year, with shares down 19% year-to-date and over 22% compared to this time last year. Those numbers might seem troubling at first glance, but a deeper...",
    "url": "https://finnhub.io/api/news?id=afdeafcf71a2933339d4fd96d8f2e6c692dce8556c6abe3d244238f2d2e5c886",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758713150,
      "headline": "Is There Now an Opportunity in Kenvue After Latest 20% Share Price Drop?",
      "id": 136862116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "If you are trying to figure out whether to hold onto your Kenvue shares, add more to your portfolio, or sit this one out, you are definitely not alone. Investors have watched Kenvue’s stock price take a hit lately, dipping 4.9% in the past week and slipping more than 20% over the last month. It has been a rough ride for the stock so far this year, with shares down 19% year-to-date and over 22% compared to this time last year. Those numbers might seem troubling at first glance, but a deeper...",
      "url": "https://finnhub.io/api/news?id=afdeafcf71a2933339d4fd96d8f2e6c692dce8556c6abe3d244238f2d2e5c886"
    }
  }
]